Federal Register / Vol. 77, No. 156 / Monday, August 13, 2012 / Notices 48165 

Health, 615 Davis Dr., KEY615/3112, 

Research Triangle Park, NC 27709, (919) 541– 

4980, collman@niehs.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.niehs.nih.gov/dert/c-agenda.htm, where 

an agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.115, Biometry and Risk 

Estimation-Health Risks from Environmental 

Exposures; 93.142, NIEHS Hazardous Waste 

Worker Health and Safety Training; 93.143, 

NIEHS Superfund Hazardous Substances— 

Basic Research and Education; 93.894, 

Resources and Manpower Development in 

the Environmental Health Sciences; 93.113, 

Biological Response to Environmental Health 

Hazards; 93.114, Applied Toxicological 

Research and Testing, National Institutes of 

Health, HHS) 

Dated: August 7, 2012. 

Carolyn A. Baum, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–19715 Filed 8–10–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Application (P01). 

Date: September 6, 2012. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Fernwood (Rockledge Campus), 

10401 Fernwood Rd., Room 2C05, Bethesda, 

MD 20892, (Telephone Conference Call) 

Contact Person: Kelly Y. Poe, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, DEA/NIAID/NIH/DHHS, 6700–B 

Rockledge Drive, MDS–7616, Bethesda, MD 

20892–7616, 301–451–2639, 

poeky@niaid.nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Clinical Trials in Organ 

Transplantation in Children. 

Date: September 10–11, 2012. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: James T. Snyder, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

DHHS/NIH/NIAID, 6700B Rockledge Drive, 

MSC 7616, Room # 3257, Bethesda, MD 

20892, 301–435–1614, james.snyder@nih.gov. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Investigator Initiated 

Program Project Application (P01). 

Date: September 12, 2012. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Fernwood (Rockledge Campus), 

10401 Fernwood Rd., Room 2C05, Bethesda, 

MD 20892, (Telephone Conference Call). 

Contact Person: Kelly Y. Poe, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, DEA/NIAID/NIH/DHHS, 6700–B 

Rockledge Drive, MDS–7616, Bethesda, MD 

20892–7616, 301–451–2639, 

poeky@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: August 7, 2012. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–19716 Filed 8–10–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Integrative 

and Functional Neurobiology. 

Date: September 5, 2012. 

Time: 2:30 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Center for Scientific Review, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Wei-Qin Zhao, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5181 

MSC 7846, Bethesda, MD 20892–7846, 301– 

435–1236, zhaow@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research; 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: August 7, 2012. 

Melanie J. Gray, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2012–19717 Filed 8–10–12; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

[Docket No. DHS–2012–0044] 

Cooperative Research and 

Development Agreement (CRADA) 

Opportunity With the Department of 

Homeland Security for the Efficacy 

Testing of Vaporous Hydrogen 

Peroxide (VHP) and Chlorine Dioxide 

(ClO2) Against Foot and Mouth Disease 

Virus (FMDV) and African Swine Fever 

Virus (ASFV) 

AGENCY: Science and Technology 

Directorate, Plum Island Animal Disease 

Center, Department of Homeland 

Security. 

ACTION: Notice of intent. 

SUMMARY: The Department of Homeland 

Security Science and Technology 

Directorate (DHS S&T), through its Plum 

Island Animal Disease Center (PIADC), 

is seeking collaborators to aid DHS S&T 

in conducting validation testing on the 

ability of VHP and ClO2 to achieve 

sufficient biological load reduction 

against live FMDV and ASFV. PIADC 

operates a Biosafety Level 3 (BSL–3) 

facility working primarily with high 

consequence foreign animal diseases. 

The nature of this work makes it 

mstockstill on DSK4VPTVN1PROD with NOTICES

48166 Federal Register / Vol. 77, No. 156 / Monday, August 13, 2012 / Notices 

paramount to ensure the effective and 

thorough decontamination of all 

material exiting the bio containment 

area within the facility. Rising health 

concerns and process efficiency/turnaround time with the use of 

formaldehyde gas (the current 

fumigation method used against FMDV 

and ASFV) are key driving factors in 

validating an alternative fumigation 

method. The fumigation method(s) will 

ultimately be used to decontaminate 

sensitive equipment and electronics, 

other material within the bio 

containment area, sealed portions of the 

facility, biological safety cabinets and 

perform in-place decontamination of 

heating, ventilation, and cooling 

(HVAC) HEPA filtration systems. The 

role of the collaborator(s) in this CRADA 

will be to provide PIADC with the 

materials, equipment, and technological 

expertise to support accurate and 

reliable efficacy testing using VHP and 

ClO2. DHS S&T is seeking CRADA 

collaborators that own the technological 

components for, have the technological 

expertise in, and have proven track 

records of success in the fields of VHP 

and ClO2 decontamination validation 

studies. The proposed term of the 

CRADA can be up to eighteen (18) 

months. 

DATES: Submit comments on or before 

September 14, 2012. 

ADDRESSES: Mail comments and 

requests to participate to Doug Ports, 

(PO Box 848, Greenport, NY 11944). 

Submit electronic comments and other 

data to Douglas.Ports@hq.dhs.gov. 

FOR FURTHER INFORMATION CONTACT: 

Information on DHS CRADAs: Marlene 

Owens, (202) 254–6671. Information on 

proposed technical effort: Doug Ports, 

(631) 323–3210. 

SUPPLEMENTARY INFORMATION: 

Efficacy Testing Plan 

The target agents (FMDV and ASFV) 

and test microorganisms (Bacillus 

subtilis, Vaccinia Virus, Geobacillius 

stearothermophilus, and potentially 

other commercially available spore 

strips) will be used to test the efficacy 

of VHP and ClO2 on various surfaces 

including balsa wood, stainless steel, 

glass, and paper. Phase I of the testing 

is set to take place at a federal laboratory 

facility against the test microorganisms, 

requiring successful results prior to 

moving on to Phase II. Phase II testing 

will take place at PIADC (Plum Island, 

NY) against both the test 

microorganisms and target agents. Phase 

I and Phase II efficacy testing will not 

require the VHP or ClO2 generators to 

enter the bio containment area; 

however, components or probes that do 

enter the bio containment area will need 

to be decontaminated using a validated 

method prior to removal. Testing and 

decontamination validation will take 

place using pre-approved methods 

agreed upon between federal and nonfederal personnel. Mutual benefits to 

both federal and non-federal 

collaborators include the opportunity to 

support the Homeland Security 

Enterprise in protecting the United 

States from internal and external foreign 

animal disease threats and response 

capabilities. Specifically, DHS S&T is 

interested in validated alternatives to 

formaldehyde fumigation with respect 

to outbreak control, infection control, 

and decontamination for FMDV and 

AFSV releases. The collaborators will 

also have the opportunity to test their 

decontamination methods directly 

against live FMDV and ASFV at the only 

laboratory in the United States, and one 

of few in the world, that works with live 

FMDV. Efficacy testing data and results 

may be published in scientific journals 

by or under the guidance of federal 

personnel. 

Period of Performance 

Once CRADA collaborators have been 

selected, finalized Phase I testing is 

expected to take approximately 3 

months. Contingent on Phase I testing 

results, Phase II testing is expected to 

take an additional 6 months and data 

consolidation, analysis, and results 

finalization is expected to take another 

3 months following. 

Selection Criteria 

The Plum Island Animal Disease 

Center (PIADC) reserves the right to 

select CRADA collaborators for all, 

some, or none of the proposals in 

response to this notice. PIADC will 

provide no funding for reimbursement 

of proposal development costs. 

Proposals (or any other material) 

submitted in response to this notice will 

not be returned. Proposals submitted are 

expected to be unclassified. 

PIADC will select proposals at its sole 

discretion on the basis of: 

i. How well the proposal 

communicates the collaborators’ 

understanding of and ability to meet the 

CRADAs goals and proposed timeline 

ii. How well the proposal addresses 

the following criteria: 

a. Capability of the collaborator to 

provide equipment and materials for 

proposed Phase I and Phase II efficacy 

testing. 

b. Capability of the collaborator to 

provide on-site and remote 

technological expertise, within a 

reasonable time period and for a 

reasonable duration, for Phase I and 

Phase II efficacy testing. 

Participation in this CRADA does not 

imply the future purchase of any 

materials, equipment or services from 

the collaborating entities; however, nonFederal CRADA participants will not be 

excluded from any future PIADC 

procurements based solely on their 

participation in this CRADA. 

Authority: CRADAs are authorized by the 

Federal Technology Transfer Act of 1986, as 

amended and codified by 15 U.S.C. 3710a. 

DHS, as an executive agency under 5 U.S.C. 

105, is a Federal agency for the purposes of 

15 U.S.C. 3710a and may enter into a 

CRADA. DHS delegated the authority to 

conduct CRADAs to the Science and 

Technology Directorate and its laboratories. 

Dated: August 7, 2012 

James Johnson, 

Director, Office of National Laboratories. 

[FR Doc. 2012–19723 Filed 8–10–12; 8:45 am] 

BILLING CODE 9110–9F–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Internal Agency Docket No. FEMA–4067– 

DR; Docket ID FEMA–2012–0002] 

Colorado; Amendment No. 2 to Notice 

of a Major Disaster Declaration 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice. 

SUMMARY: This notice amends the notice 

of a major disaster declaration for the 

State of Colorado (FEMA–4067–DR), 

dated June 28, 2012, and related 

determinations. 

DATES: Effective Date: August 6, 2012. 

FOR FURTHER INFORMATION CONTACT: 

Peggy Miller, Office of Response and 

Recovery, Federal Emergency 

Management Agency, 500 C Street SW., 

Washington, DC 20472, (202) 646–3886. 

SUPPLEMENTARY INFORMATION: The notice 

of a major disaster declaration for the 

State of Colorado is hereby amended to 

include the Hazard Mitigation Grant 

Program for the following areas among 

those areas determined to have been 

adversely affected by the event declared 

a major disaster by the President in his 

declaration of June 28, 2012. 

All counties in the State of Colorado are 

eligible to apply for assistance under the 

Hazard Mitigation Grant Program. 

(The following Catalog of Federal Domestic 

Assistance Numbers (CFDA) are to be used 

for reporting and drawing funds: 97.030, 

Community Disaster Loans; 97.031, Cora 

mstockstill on DSK4VPTVN1PROD with NOTICES